Oncology Search
Oncology Oncology
cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Introduction

  • Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival
    • Chronic pain syndrome also often occurs following cancer treatments
  • Pancreatic, head & neck cancer has a high prevalence of cancer pain
  • During initial evaluation, follow-ups & new therapy initiation of patients with cancer, it is essential that they be screened & evaluated for pain

Definition

  • An unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Gilteritinib improves survival in relapsed or refractory AML
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Two studies highlight potential of third-line pembrolizumab in advanced SCLC
Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.